Adaptimmune Therapeutics Plc - ADR

-0.11 (-9.56%)
Products, Regulatory

Adaptimmune Reports Positive Data In Its Surpass Trial Outlines Plans For Advanced Clinical Development In Multiple Mage-A4 Positive Solid Tumors

Published: 09/09/2022 11:30 GMT
Adaptimmune Therapeutics Plc - ADR (ADAP) - Adaptimmune Reports Positive Data in Its Surpass Trial; Outlines Plans for Advanced Clinical Development in Multiple Mage-a4 Positive Solid Tumors.
Adaptimmune - Across All Tumor Types in Surpass Trial, Responses Observed in Five Solid Tumor Types in 43 Heavily Pre-treated Patients With Orr of 33%.
Adaptimmune - Across Non-sarcoma Tumors, Significantly Higher Response Rates Compared With the First-generation Mage-a4 Targeted Product.
Adaptimmune - Further Clinical Development Planned in Ovarian (surpass-3), Urothelial, and Head & Neck Cancers.
Adaptimmune - 44% Orr With Single Dose of Adp-a2m4cd8 in 25 Heavily Pre-treated Patients With Late-stage Ovarian, Urothelial, and Head & Neck Cancers.